Michiga subcutaneous injection 60 mg syringe

Michiga subcutaneous injection 60 mg syringe, manufactured by Maruho, contains nemolizumab (genetical recombination). This monoclonal antibody is approved in Japan for the treatment of pruritus associated with moderate-to-severe atopic dermatitis in patients aged 13 years and older, when other treatments are insufficient. The 60mg 1 tube formulation has a YJ code of 4490408G1028.